JP6993984B2 - 変異ボルデテラ菌株および使用方法 - Google Patents

変異ボルデテラ菌株および使用方法 Download PDF

Info

Publication number
JP6993984B2
JP6993984B2 JP2018551960A JP2018551960A JP6993984B2 JP 6993984 B2 JP6993984 B2 JP 6993984B2 JP 2018551960 A JP2018551960 A JP 2018551960A JP 2018551960 A JP2018551960 A JP 2018551960A JP 6993984 B2 JP6993984 B2 JP 6993984B2
Authority
JP
Japan
Prior art keywords
subject
pertactin
use according
mice
bordetella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018551960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513722A5 (enExample
JP2019513722A (ja
Inventor
ソラン，ルイ
ロヒト，カミーレ
ツィコプーロス，アン
ヤイア センディド，サリハ アイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Pasteur de Lille
Publication of JP2019513722A publication Critical patent/JP2019513722A/ja
Publication of JP2019513722A5 publication Critical patent/JP2019513722A5/ja
Application granted granted Critical
Publication of JP6993984B2 publication Critical patent/JP6993984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
JP2018551960A 2016-03-29 2017-03-29 変異ボルデテラ菌株および使用方法 Active JP6993984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
US62/314,843 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Publications (3)

Publication Number Publication Date
JP2019513722A JP2019513722A (ja) 2019-05-30
JP2019513722A5 JP2019513722A5 (enExample) 2020-04-02
JP6993984B2 true JP6993984B2 (ja) 2022-02-03

Family

ID=58488973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018551960A Active JP6993984B2 (ja) 2016-03-29 2017-03-29 変異ボルデテラ菌株および使用方法

Country Status (11)

Country Link
US (4) US10682377B2 (enExample)
EP (2) EP4541809A3 (enExample)
JP (1) JP6993984B2 (enExample)
CN (2) CN114767718A (enExample)
AU (2) AU2017242541B2 (enExample)
CA (1) CA3018126A1 (enExample)
DK (1) DK3436034T3 (enExample)
ES (1) ES3027194T3 (enExample)
FI (1) FI3436034T3 (enExample)
SG (1) SG11201807783UA (enExample)
WO (1) WO2017167834A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707102B1 (pt) * 2006-03-10 2022-05-31 Institut Pasteur De Lille Composição imunogênica
CA2759280C (en) 2009-04-28 2016-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
AU2017242541B2 (en) * 2016-03-29 2022-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutant bordetella strains and methods for use
CA3077428A1 (en) 2017-10-18 2019-04-25 Institut Pasteur De Lille Bordetella strains expressing serotype 3 fimbriae
BR112023002549A2 (pt) 2020-08-14 2023-03-07 Iliad Biotechnologies Llc Método de fabricação de uma vacina liofilizada compreendendo bactérias bordetella vivas atenuadas e produto de vacina liofilizada
CN116635517A (zh) 2020-11-17 2023-08-22 伊利亚德生物技术有限公司 与神经退行性疾病相关的神经病理的治疗和预防
JP2025525623A (ja) 2022-07-22 2025-08-05 アンスティチュ ナシヨナル デュ ラ サンテ エト デュ ラ レシェルシェ メディカレ 慢性閉塞性肺疾患の治療のためのボルデテラ（ｂｏｒｄｅｔｅｌｌａ）菌株の使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507568A (ja) 1996-10-11 2001-06-12 アンスティテュ パストゥール ド リール ハイブリッドｆｈａを発現するボルデテラ株、リポソームおよびワクチン
JP2012525346A (ja) 2009-04-28 2012-10-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アレルゲン駆動性気道病態の予防または治療のためのワクチン
WO2013066272A1 (en) 2011-11-02 2013-05-10 National University Of Singapore Effect of an attenuated bordetella strain against allergic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
CN1147259A (zh) * 1994-04-28 1997-04-09 武田药品工业株式会社 分离百日咳杆菌保护性组分的方法
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
EP1617805A4 (en) 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
BRPI0707102B1 (pt) 2006-03-10 2022-05-31 Institut Pasteur De Lille Composição imunogênica
WO2008058396A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
EP2134359A4 (en) 2007-02-23 2010-06-16 Penn State Res Found USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR
US20100104533A1 (en) 2007-06-18 2010-04-29 Carter William A Early intervention of viral infection with immune activators
JP5551774B2 (ja) 2009-06-15 2014-07-16 ナショナル ユニヴァーシティー オブ シンガポール インフルエンザワクチン、組成物、および使用方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
AU2017242541B2 (en) * 2016-03-29 2022-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutant bordetella strains and methods for use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507568A (ja) 1996-10-11 2001-06-12 アンスティテュ パストゥール ド リール ハイブリッドｆｈａを発現するボルデテラ株、リポソームおよびワクチン
JP2012525346A (ja) 2009-04-28 2012-10-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アレルゲン駆動性気道病態の予防または治療のためのワクチン
WO2013066272A1 (en) 2011-11-02 2013-05-10 National University Of Singapore Effect of an attenuated bordetella strain against allergic disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Euro Surveill，2014年，Vol.19, No.33，pii=20881
PLOS ONE, 2014，Vol.9, No.1，e83449

Also Published As

Publication number Publication date
EP4541809A3 (en) 2025-06-25
FI3436034T3 (fi) 2025-05-08
US11065276B2 (en) 2021-07-20
CN114767718A (zh) 2022-07-22
EP3436034B1 (en) 2025-03-26
AU2022221438B2 (en) 2024-10-03
JP2019513722A (ja) 2019-05-30
EP3436034A1 (en) 2019-02-06
US20170283890A1 (en) 2017-10-05
DK3436034T3 (da) 2025-05-12
CN109069535B (zh) 2022-03-18
AU2017242541B2 (en) 2022-06-30
US10682377B2 (en) 2020-06-16
CN109069535A (zh) 2018-12-21
AU2017242541A1 (en) 2018-10-11
AU2022221438A1 (en) 2022-10-06
EP4541809A2 (en) 2025-04-23
US20200323901A1 (en) 2020-10-15
SG11201807783UA (en) 2018-10-30
US20210290667A1 (en) 2021-09-23
ES3027194T3 (en) 2025-06-13
WO2017167834A1 (en) 2017-10-05
CA3018126A1 (en) 2017-10-05
US20230381224A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
JP6993984B2 (ja) 変異ボルデテラ菌株および使用方法
Solans et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
US12403188B2 (en) Bordetella strains expressing serotype 3 fimbriae
JP2019513722A5 (enExample)
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
WO2020049133A1 (en) Adenylate cyclase catalytic domain deficient bordetella strains
Mann et al. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine
EP0535740B1 (en) Respiratory disease vaccine for cats
CN112449604A (zh) 用作有结核感染风险的患者的预防剂或用作治疗结核感染患者的辅助剂的组合物
HK1262896B (zh) 突变型博德特氏菌属菌株及其使用方法
HK1262896A1 (en) Mutant bordetella strains and methods for use
JP6867623B2 (ja) 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法
Oyant et al. Role of Bordetella bronchiseptica adenylate cyclase in nasal colonization and in development of local and systemic immune responses in piglets
HK40026630B (zh) 表达血清3型菌毛的鲍特菌属菌株
JP2023550052A (ja) 神経変性疾患に関連する神経病理の治療および予防
HK40026630A (en) Bordetella strains expressing serotype 3 fimbriae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211210

R150 Certificate of patent or registration of utility model

Ref document number: 6993984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250